Anuh Pharma Ltd

Anuh Pharma Ltd has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a nuanced change in investor sentiment. Despite a recent day gain of 2.54%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring the need for cautious analysis in the Pharmaceuticals & Biotechnology sector.

Anuh Pharma Ltd (Stock ID: 905552) has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite some mildly bullish weekly indicators, the overall technical landscape remains cautious, with key metrics such as moving averages and monthly MACD signalling downward pressure. This article analyses the recent technical parameter changes, price momentum, and how these signals align with the broader market context.

Anuh Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 February 2026, providing investors with the most recent insights into the company’s performance and outlook.

Anuh Pharma Ltd, a player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish trend. Despite a recent day gain of 3.73%, the company’s technical indicators present a complex picture, with some signals suggesting cautious optimism while others remain subdued. This article analyses the latest technical parameters, price momentum, and relative performance against the broader market to provide a comprehensive view for investors.

Anuh Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven primarily by a decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This revaluation comes amid a mixed performance backdrop in the Pharmaceuticals & Biotechnology sector, where peer comparisons and historical benchmarks provide a nuanced perspective on the stock’s price attractiveness and investment potential.

Anuh Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite some mildly bullish weekly signals, the overall technical landscape suggests caution for investors as the stock navigates downward pressures amid mixed momentum readings.

Anuh Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Anuh Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, supported by mixed signals from key technical indicators. Despite a recent 4.34% gain in the stock price, the company’s overall Mojo Grade remains a Sell, reflecting cautious sentiment amid volatile market conditions and sectoral challenges.

Anuh Pharma Ltd., a leading manufacturer of Active Pharmaceutical Ingredients (APIs), has delivered a mixed performance in its latest results, with the stock trading at ₹79.74 on February 6, 2026, down 21.55% over the past year. The Mumbai-based micro-cap company, with a market capitalisation of ₹800 crores, faces mounting pressure from persistent margin erosion despite achieving strong nine-month revenue growth of 22.91% in FY2026.

Anuh Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Recent technical indicators including MACD, RSI, and moving averages signal increasing downside pressure, reflecting challenges in the Pharmaceuticals & Biotechnology sector. This article analyses the evolving technical landscape and what it means for investors amid broader market conditions.

Anuh Pharma Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a nuanced improvement in its technical outlook and valuation metrics despite ongoing financial challenges. The pharmaceutical company’s recent performance across quality, valuation, financial trends, and technical indicators has prompted a reassessment of its market stance, signalling cautious optimism amid persistent headwinds.

Anuh Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, supported by a blend of bullish and bearish signals across key indicators. Despite a strong weekly price surge of 4.22% to close at ₹82.78, the stock’s medium- and long-term technicals reveal a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Anuh Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Anuh Pharma Ltd’s shares touched a fresh 52-week low of Rs.68 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial performance and market positioning.

Anuh Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Anuh Pharma Ltd’s shares declined to a fresh 52-week low of Rs.71.6 on 20 Jan 2026, marking a significant downturn for the pharmaceutical company amid broader market weakness and company-specific performance issues.